BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

598 related articles for article (PubMed ID: 19113797)

  • 1. Antipsychotic-induced hyperprolactinemia.
    Bostwick JR; Guthrie SK; Ellingrod VL
    Pharmacotherapy; 2009 Jan; 29(1):64-73. PubMed ID: 19113797
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical implications of antipsychotic-induced hyperprolactinemia in patients with schizophrenia spectrum or bipolar spectrum disorders: recent developments and current perspectives.
    Byerly M; Suppes T; Tran QV; Baker RA
    J Clin Psychopharmacol; 2007 Dec; 27(6):639-61. PubMed ID: 18004132
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Antipsychotic-drug-induced hyperprolactinemia: physiopathology, clinical features and guidance].
    Besnard I; Auclair V; Callery G; Gabriel-Bordenave C; Roberge C
    Encephale; 2014 Feb; 40(1):86-94. PubMed ID: 23928066
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prolactin elevation with antipsychotic medications: mechanisms of action and clinical consequences.
    Maguire GA
    J Clin Psychiatry; 2002; 63 Suppl 4():56-62. PubMed ID: 11913677
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antipsychotic-induced hyperprolactinemia and sexual dysfunction.
    Compton MT; Miller AH
    Psychopharmacol Bull; 2002; 36(1):143-64. PubMed ID: 12397853
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hyperprolactinaemia and antipsychotic therapy in schizophrenia.
    Hummer M; Huber J
    Curr Med Res Opin; 2004; 20(2):189-97. PubMed ID: 15006013
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of antipsychotics on sexual and endocrine function in women: implications for clinical practice.
    Smith S
    J Clin Psychopharmacol; 2003 Jun; 23(3 Suppl 1):S27-32. PubMed ID: 12832947
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antipsychotic-induced hyperprolactinaemia, hypogonadism and osteoporosis in the treatment of schizophrenia.
    O'Keane V
    J Psychopharmacol; 2008 Mar; 22(2 Suppl):70-5. PubMed ID: 18477623
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prolactin awareness: an essential consideration for physical health in schizophrenia.
    Montejo AL
    Eur Neuropsychopharmacol; 2008 May; 18 Suppl 2():S108-14. PubMed ID: 18346598
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risperidone-induced symptomatic hyperprolactinaemia in adolescents.
    Holzer L; Eap CB
    J Clin Psychopharmacol; 2006 Apr; 26(2):167-71. PubMed ID: 16633146
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Management of psychotropic-induced hyperprolactinemia.
    Marken PA; Haykal RF; Fisher JN
    Clin Pharm; 1992 Oct; 11(10):851-6. PubMed ID: 1341991
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The evolution of hyperprolactinaemia as an entity in psychiatric patients.
    Kohen D; Wildgust HJ
    J Psychopharmacol; 2008 Mar; 22(2 Suppl):6-11. PubMed ID: 18477616
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antipsychotic-induced hyperprolactinaemia.
    Inder WJ; Castle D
    Aust N Z J Psychiatry; 2011 Oct; 45(10):830-7. PubMed ID: 21714721
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management.
    Haddad PM; Wieck A
    Drugs; 2004; 64(20):2291-314. PubMed ID: 15456328
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antipsychotic-induced hyperprolactinemia: a cross-sectional survey.
    Johnsen E; Kroken RA; Abaza M; Olberg H; Jørgensen HA
    J Clin Psychopharmacol; 2008 Dec; 28(6):686-90. PubMed ID: 19011438
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Medical causes and consequences of hyperprolactinaemia. A context for psychiatrists.
    Holt RI
    J Psychopharmacol; 2008 Mar; 22(2 Suppl):28-37. PubMed ID: 18477618
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Antipsychotic-induced symptomatic hyperprolactinemia: clinical consequences and therapeutic strategies].
    Pollice R; Di Giovambattista E; Tomassini A; Di Pucchio A; Ussorio D; Roncone R; Casacchia M
    Clin Ter; 2007; 158(2):173-9. PubMed ID: 17566521
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hyperprolactinemia in a patient with a pituitary adenoma receiving antipsychotic drug therapy.
    Carroll RW; Christodoulou P; Baynes KC; Kahn DA
    J Psychiatr Pract; 2012 Mar; 18(2):126-9. PubMed ID: 22418404
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Antipsychotics and hyperpolactinaemia: pathophysiology, clinical relevance, diagnosis and therapy].
    Riecher-Rössler A; Schmid C; Bleuer S; Birkhäuser M
    Neuropsychiatr; 2009; 23(2):71-83. PubMed ID: 19573500
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased incidence of autoimmune thyroiditis in patients with antipsychotic-induced hyperprolactinemia.
    Poyraz BC; Aksoy C; Balcioğlu I
    Eur Neuropsychopharmacol; 2008 Sep; 18(9):667-72. PubMed ID: 18539008
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.